Non-Hodgkin's lymphomas, version 2.2014 Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin
  • Neoplasm Recurrence, Local

abstract

  • Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

authors

publication date

  • June 2014

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 24925202

Additional Document Info

start page

  • 916

end page

  • 46

volume

  • 12

number

  • 6